Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Zepbound trims more belly fat than Wegovy, study shows Lilly, which funded the research, is leapfrogging Novo in the booming market for powerful new obesity medicines.

Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.

Zepbound is a prescription drug used for weight loss and weight management in adults. Learn about the drug's dosage, form, strengths, how to use, and more.

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.